Compare iShares MSCI Indonesia ETF (EIDO) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Indonesia ETF vs Stryker Corporation — how do they compare? iShares MSCI Indonesia ETF trades at $11.89 (market cap $409.22M), while Stryker Corporation trades at $277.33 (market cap $106.24B). The key difference: Stryker Corporation is far larger — about 259.6× iShares MSCI Indonesia ETF's market cap, and Stryker Corporation pays a 1.27% dividend while iShares MSCI Indonesia ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Indonesia ETF for 76 Days and Stryker Corporation for 21 Days on average.
| EIDO | SYK | |
|---|---|---|
Market Cap | $409.22M | $106.24B |
Volume | 879,527 | 2,982,001 |
52-Week High | $19.22 | $388.35 |
52-Week Low | $10.80 | $269.75 |
Typical Hold Time | 76 Days | 21 Days |
Sector | — | Health |
Enterprise Value | — | $117.70B |
Dividend Yield | — | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EIDO trades at $11.67, down 1.6% on the day, with technical indicators showing a bearish trend as moving averages signal strong selling pressure. The ETF's financial ratios are not disclosed in available data, but recent news highlights its exposure to Indonesian equities and a challenging technical downtrend. Trading volume remains active, though recent sessions show a decline from average levels.
The outlook for EIDO is cautious due to weak price action and sector concentration risks, with limited upside from low earnings growth. Key risks include dependence on financials and commodity markets, while potential opportunities may arise from seasonal trends or valuation rebounds if investor sentiment improves.
Stryker (SYK) trades at $276.97, up 0.57% today, amid a bearish technical signal with key support at $274 and resistance at $279. The company reported strong profitability with a 14.43% net income margin and beat Q2 2026 EPS estimates, though it missed in Q1. Recent news highlights ongoing legal scrutiny related to manufacturing issues disclosed in September 2026, which caused a significant share price drop.
Analyst consensus remains strongly bullish with a $368.11 price target, but risks include persistent manufacturing problems and potential securities litigation. Earnings growth and margin expansion support the long-term outlook, though near-term volatility may persist pending Q3 2026 results on October 29, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Indonesia ETF
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
